ATE512148T1 - Pyrazolo- und imidazopyrimidinderivate - Google Patents

Pyrazolo- und imidazopyrimidinderivate

Info

Publication number
ATE512148T1
ATE512148T1 AT04765633T AT04765633T ATE512148T1 AT E512148 T1 ATE512148 T1 AT E512148T1 AT 04765633 T AT04765633 T AT 04765633T AT 04765633 T AT04765633 T AT 04765633T AT E512148 T1 ATE512148 T1 AT E512148T1
Authority
AT
Austria
Prior art keywords
imidazopyrimide
pyrazolo
derivatives
imidazopyrimide derivatives
Prior art date
Application number
AT04765633T
Other languages
English (en)
Inventor
Juergen Wichmann
Thomas Woltering
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE512148T1 publication Critical patent/ATE512148T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Otolaryngology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT04765633T 2003-10-03 2004-09-27 Pyrazolo- und imidazopyrimidinderivate ATE512148T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03078075 2003-10-03
PCT/EP2004/010807 WO2005040171A1 (en) 2003-10-03 2004-09-27 Pyrazolo and imidazo-pyrimidine derivatives

Publications (1)

Publication Number Publication Date
ATE512148T1 true ATE512148T1 (de) 2011-06-15

Family

ID=34486287

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04765633T ATE512148T1 (de) 2003-10-03 2004-09-27 Pyrazolo- und imidazopyrimidinderivate

Country Status (20)

Country Link
US (2) US7329662B2 (de)
EP (1) EP1670801B1 (de)
JP (1) JP4551402B2 (de)
KR (2) KR100781469B1 (de)
CN (2) CN100522964C (de)
AR (1) AR045959A1 (de)
AT (1) ATE512148T1 (de)
AU (1) AU2004283801B2 (de)
BR (1) BRPI0414948A (de)
CA (1) CA2540768C (de)
CO (1) CO5680437A2 (de)
ES (1) ES2364753T3 (de)
IL (1) IL174512A0 (de)
MX (1) MXPA06003526A (de)
NO (1) NO20061363L (de)
NZ (1) NZ546037A (de)
RU (1) RU2350616C2 (de)
TW (1) TWI297691B (de)
WO (1) WO2005040171A1 (de)
ZA (1) ZA200602677B (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7329662B2 (en) * 2003-10-03 2008-02-12 Hoffmann-La Roche Inc. Pyrazolo-pyridine
CA2571487C (en) * 2004-06-21 2013-04-30 F. Hoffmann-La Roche Ag Pyrrazolo-pyrimidine derivatives
JP4708438B2 (ja) * 2005-02-11 2011-06-22 エフ．ホフマン−ラ ロシュ アーゲー ｍＧｌｕＲ２アンタゴニストとしてのピラゾロピリミジン誘導体
JP4801724B2 (ja) 2005-03-23 2011-10-26 エフ．ホフマン−ラ ロシュ アーゲー ｍＧｌｕＲ２アンタゴニストとしてのアセチレニル−ピラゾロ−ピリミジン誘導体
ES2340321T3 (es) 2005-09-27 2010-06-01 F.Hoffmann-La Roche Ag Oxadiazolilpirazolo-pirimidinas, como antagonistas de mglur2.
US8461162B2 (en) * 2007-07-20 2013-06-11 Merck Sharp & Dohme Corp. Pyrazolo[1,5-a]pyrimidine derivatives
CN101671336B (zh) * 2009-09-23 2013-11-13 辽宁利锋科技开发有限公司 芳杂环并嘧啶衍生物和类似物及其制备方法和用途
US9447099B2 (en) * 2011-10-04 2016-09-20 Hoffmann-La Roche Inc. Methods for the preparation of 5-[2-[7 (trifluoromethyl)-5-[4-(trifluoromethyl)phenyl]pyrazolo [1,5-A]pyrimidin-3-yl[ethynyl]-2-pyridinamine
WO2014017938A2 (en) * 2012-07-27 2014-01-30 BIAL - PORTELA & Cª, S.A. Process for the synthesis of substituted urea compounds
BR112015008297A2 (pt) 2012-10-23 2017-07-04 Hoffmann La Roche antagonistas de mglu2/3 para o tratamento de distúrbios autistas
CA2898294C (en) 2013-02-21 2020-06-09 Calitor Sciences, Llc Heteroaromatic compounds as pi3 kinase modulators
TW201542550A (zh) 2013-09-06 2015-11-16 Lexicon Pharmaceuticals Inc 吡唑并［１，５－ａ］嘧啶基化合物、包含彼之組合物以及使用彼之方法
CN104193745B (zh) * 2014-07-30 2016-09-28 斯芬克司药物研发（天津）股份有限公司 一种咪唑并嘧啶羧酸类化合物及其制备方法
WO2016016382A1 (en) * 2014-08-01 2016-02-04 Janssen Pharmaceutica Nv 6,7-dihydropyrazolo[1,5-a]pyrazin-4(5h)-one compounds and their use as negative allosteric modulators of mglur2 receptors
EP3000814A1 (de) 2014-09-26 2016-03-30 Domain Therapeutics Substituierte Pyrazolochinazolinone und Pyrrolochinazolinone als allosterische Modulatoren von metabotropen Glutamatrezeptoren der Gruppe II
EP3226915B1 (de) 2014-12-03 2019-02-20 Janssen Pharmaceutica NV Radioaktiv markierte mglur2-pet-liganden
TWI713497B (zh) * 2015-02-26 2020-12-21 南韓商愛思開生物製藥股份有限公司 咪唑并嘧啶及咪唑并三衍生物及包含該衍生物之醫藥組成物
HK1255330A1 (zh) 2015-08-26 2019-08-16 缆图药品公司 适用於治疗与ntrk相关的病症的化合物和组合物
MX2018006195A (es) 2015-11-19 2018-09-05 Blueprint Medicines Corp Compuestos y composiciones utiles para el tratamiento de trastornos relacionados con ntrk.
US11033641B2 (en) 2015-12-18 2021-06-15 Janssen Pharmaceutica Nv Radiolabelled mGluR2/3 pet ligands
EP3389728B1 (de) 2015-12-18 2020-08-05 Janssen Pharmaceutica NV Radioaktiv markierte mglur2/3 pet-liganden
CN111868063B (zh) * 2018-01-17 2023-08-01 葛兰素史克知识产权开发有限公司 PI4KIIIβ抑制剂
WO2025002289A1 (zh) * 2023-06-29 2025-01-02 湖南九典制药股份有限公司 一种吡唑并杂芳基类化合物及其制备方法和应用
CN116836110B (zh) * 2023-06-30 2026-02-10 天津均凯农业科技有限公司 一种2-氨乙基-3-氯-5-三氟甲基吡啶盐酸盐的制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0880523B1 (de) 1996-02-07 2006-08-16 Neurocrine Biosciences, Inc. Pyrazolopyrimidine als crf rezeptor-antagonisten
PL195762B1 (pl) * 1996-07-24 2007-10-31 Bristol Myers Squibb Pharma Co Związki [1,5-a]pirazolo-1,3,5-triazynowe, środek farmaceutyczny i zastosowanie związków [1,5-a]pirazolo-1,3,5-triazynowych do wytwarzania leku
PT891978E (pt) 1997-07-18 2002-07-31 Hoffmann La Roche Derivados de 5h-tiazolo (3,2-a) pirimidina
AU4203500A (en) 1999-04-06 2000-10-23 Du Pont Pharmaceuticals Company Pyrazolopyrimidines as crf antagonists
YU79003A (sh) 2001-04-12 2006-05-25 F. Hoffmann-La Roche Ag. Derivati dihidro-benzo/b/ /1,4/diazepin-2-ona kao mglur2 antagonisti ii
GB0128499D0 (en) 2001-11-28 2002-01-23 Merck Sharp & Dohme Therapeutic agents
CA2468067A1 (en) * 2001-11-30 2003-06-12 Merck & Co., Inc. Metabotropic glutamate receptor-5 modulators
US7329662B2 (en) * 2003-10-03 2008-02-12 Hoffmann-La Roche Inc. Pyrazolo-pyridine

Also Published As

Publication number Publication date
HK1099302A1 (zh) 2007-08-10
KR100781469B1 (ko) 2007-12-03
US7514443B2 (en) 2009-04-07
EP1670801A1 (de) 2006-06-21
CN101239981B (zh) 2011-01-19
CA2540768C (en) 2011-08-09
CN1890242A (zh) 2007-01-03
TW200528453A (en) 2005-09-01
TWI297691B (en) 2008-06-11
CA2540768A1 (en) 2005-05-06
EP1670801B1 (de) 2011-06-08
JP2007507446A (ja) 2007-03-29
RU2006114749A (ru) 2007-11-20
RU2350616C2 (ru) 2009-03-27
NZ546037A (en) 2008-09-26
IL174512A0 (en) 2006-08-01
CN101239981A (zh) 2008-08-13
KR20060089731A (ko) 2006-08-09
NO20061363L (no) 2006-04-24
BRPI0414948A (pt) 2006-11-07
WO2005040171A1 (en) 2005-05-06
MXPA06003526A (es) 2006-06-08
AU2004283801A1 (en) 2005-05-06
US20080051421A1 (en) 2008-02-28
US7329662B2 (en) 2008-02-12
WO2005040171A8 (en) 2006-08-03
JP4551402B2 (ja) 2010-09-29
ZA200602677B (en) 2007-09-26
US20050130992A1 (en) 2005-06-16
KR20070096033A (ko) 2007-10-01
AU2004283801B2 (en) 2010-04-22
AR045959A1 (es) 2005-11-16
CN100522964C (zh) 2009-08-05
CO5680437A2 (es) 2006-09-29
ES2364753T3 (es) 2011-09-13

Similar Documents

Publication Publication Date Title
ATE512148T1 (de) Pyrazolo- und imidazopyrimidinderivate
IS7872A (is) Pýrrólópýrimidín afleiður
DK1611131T3 (da) Pyrazolopyridin-derivater
DE602004019294D1 (de) Tetrahydronaphthalin- und harnstoffderivate
ATE340782T1 (de) Piperidinbenzolsulfonamidderivate
ATE478870T1 (de) Spiroindolinpiperidinderivate
DK1556385T3 (da) Heterocyclocarboxamid-derivater
DK1551802T3 (da) Indol-3-svovlderivater
ATE467631T1 (de) Chinuclidinamidderivate
ATE438644T1 (de) Chinazolinderivate
IS7720A (is) Píperidín-N-oxíð-afleiður
DK1474408T3 (da) N-Phenyl-2-pyrimidinaminderivater
ATE352550T1 (de) Chinazolinderivate
ATE420066T1 (de) Amidoacetonitrilderivate
DK1606277T3 (da) Imidazol-4-yl-ethynyl-pyridinderivater
DK1675852T3 (da) Heterocykliske 7-amino-alkylidenyl-quinoloner og -naphthyridoner
DE502004011106D1 (de) 6-arylmethyl-substituierte pyrazolopyrimidine
ATE335729T1 (de) 3h-chinazoline -4-on derivaten
DK1682129T3 (da) N-thiazol-2-ylbenzamidderivater
ATE423771T1 (de) Tetrahydrochinolinderivate
DK1706373T3 (da) Amidoacetonitrilderivater
IS8045A (is) Púrín-6-ón-afleiður
DE50306277D1 (de) 4-alkyl-/4-alkenyl-/4-alkinylmethyl/-1-arylcyclohexylamin-derivate
GB0307231D0 (en) 7-Nitroindoline derivatives and their uses
IS7906A (is) Afleiður própargýl-tríflúorómetoxý-amínó-benzóþíazóls

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1670801

Country of ref document: EP